NDA 206316 · Daiichi Sankyo INC
Savaysa
Edoxaban Tosylate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Oct 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 8, 2015
Approved uses
5
Original approval plus efficacy supplements
Registered trials
123
38 Phase 3, 19 recruiting
FAERS reports
6,825
6,132 serious, 899 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning. (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients...
What it is approved for
From the label in effect Jul 10, 2025.
SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 ) 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) and Clinical Studies (14.1) ] . 1.2 Treatment of Deep Vein Thrombosis and Pulmonary Embolism SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
Mechanism: Edoxaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Edoxaban inhibits free FXa, and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of FXa in the coagulation cascade reduces thrombin generation and reduces thrombus formation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2023 Supplement 19 · Efficacy LetterLabelMedication Guide
- Oct 18, 2023 Supplement 21 · Efficacy
- Aug 9, 2019 Supplement 15 · Efficacy LabelLetter
- Jan 8, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewFDA Press Release
- Jan 8, 2015 Original approval · Efficacy Novel
3 products under this application
- SAVAYSA · EDOXABAN TOSYLATE EQ 60MG BASE · TABLET, ORAL · Prescription
- SAVAYSA · EDOXABAN TOSYLATE EQ 15MG BASE · TABLET, ORAL · Prescription
- SAVAYSA · EDOXABAN TOSYLATE EQ 30MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Edoxaban" as an intervention, any sponsor and status, largest first.
- Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial FibrillationPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00781391 · 21,105 participants · Start Nov 2008 · Primary completion Apr 2013
Drug: warfarin tablets; Edoxaban tablets (high dose regimen-60mg) and 3 more · For: Stroke; Atrial Fibrillation; Embolism
Sites: Birmingham, Alabama; Mobile, Alabama; Gilbert, Arizona · 1,009 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129490 · 11,000 participants (planned) · Start Apr 1, 2023 · Primary completion Oct 30, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Atrial Fibrillation; Atrial Flutter
Sites: Aalborg, Denmark; Aarhus, Denmark; Ballerup Municipality, Denmark · 38 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00986154 · 8,292 participants · Start Oct 2009 · Primary completion Apr 2013
Drug: edoxaban tosylate(DU-176b); low molecular weight heparin/unfractionated heparin and 1 more · For: Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE) and 2 more
Sites: Mobile, Alabama; Montgomery, Alabama; Phoenix, Arizona · 454 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Pivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129555 · 5,000 participants (planned) · Start Apr 1, 2023 · Primary completion Mar 31, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Deep Vein Thrombosis; Pulmonary Embolism
Sites: Aarhus, Denmark; Copenhagen, Denmark; Copenhagen NV, Denmark · 26 sites in all
- Edoxaban for TIA and Acute Minor StrokePivotal-lookingStatus unknown
Xijing HospitalAcademic, hospital or other
NCT02221102 · 3,700 participants (planned) · Start Dec 2013 · Primary completion Jun 2015
Drug: Aspirin; edoxaban and 1 more · For: Ischemia; Stroke; Cerebral Infarction
Sites: Xi'an, China
- OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled TrialPivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT03759938 · 3,648 participants · Start Jun 18, 2019 · Primary completion May 30, 2024
Drug: Direct oral anticoagulant (DOAC) · For: Stroke, Acute; Atrial Fibrillation
Sites: Aberystwyth, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 44 sites in all
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialPivotal-lookingRecruiting
Population Health Research InstituteAcademic, hospital or other
NCT04284839 · 3,500 participants (planned) · Start Jul 18, 2021 · Primary completion Jun 2027
Drug: DOAC; VKA · For: Bleeding Post Cardiac Surgery; Indication for Anticoagulation
Sites: Fitzroy, Australia; Parkville, Australia; Edmonton, Canada · 19 sites in all
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGPivotal-lookingRecruiting
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT04045665 · 3,200 participants (planned) · Start Dec 13, 2019 · Primary completion Aug 31, 2026
Drug: Antiplatelet-only strategy; Oral Anticoagulant plus background antiplatelet therapy · For: Atrial Fibrillation; Stroke; Bleeding
Sites: Little Rock, Arkansas; Los Angeles, California; Stanford, California · 106 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaemia329
- off label use323
- renal impairment295
- dyspnoea274
- cerebral infarction273
- cardiac failure270
- nausea247
- atrial fibrillation226
- pneumonia224
- diarrhoea216
- fall214
- gastrointestinal haemorrhage207
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2015 | 345 |
| 2016 | 253 |
| 2017 | 130 |
| 2018 | 77 |
| 2019 | 96 |
| 2020 | 119 |
| 2021 | 569 |
| 2022 | 1,151 |
| 2023 | 1,178 |
| 2024 | 1,188 |
| 2025 | 993 |
| 2026 | 725 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Savaysa (Edoxaban Tosylate)
2024 spending
$5.1M
Beneficiaries
1,536
7,868 claims
Per beneficiary
$3,331
$13.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,799,760 |
| 2021 | $6,659,333 |
| 2022 | $5,817,571 |
| 2023 | $5,343,976 |
| 2024 | $5,115,977 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review.
Chopard R, Albertsen IE, Piazza G · JAMA 2020 · Systematic Review
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Key NS, Khorana AA, Kuderer NM, et al. · J Clin Oncol 2020 · Practice Guideline, Systematic Review
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, et al. · N Engl J Med 2020 · Equivalence Trial, Multicenter Study
- Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, et al. · N Engl J Med 2013 · Comparative Study, Multicenter Study
- Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K, Akao M, Yoshida T, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
Cho MS, Kang DY, Ahn JM, et al. · N Engl J Med 2024 · Clinical Trial, Phase IV, Comparative Study
Sponsor: Daiichi Sankyo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.